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Bone Marrow Acid Phosphatase 
in the Evaluation of Patients 
with Carcinoma of the Prostate 
Ronald Kabler, M D * , Riad Farah, M D * , 
Kenneth Greenawald, MD, PhD**, and Joseph C. Cerny, MD* 
Based on experience with 30 men having 
clinical stage A and B adenocarcinoma of 
the prostate, the authors conclude that ele-
vation of bone marrow acid phosphatase 
(BMAP) is a sensitive indicator of the disease 
state. BMAP revealed periprostatic or nodal 
Involvement when osseous metastases 
seemed absent. BMAP is considered essen-
tial in the evaluation of all patients with 
prostatic carcinoma. Patients who have false 
negative BMAP (and are not candidates for 
radical prostatectomy), should undergo 
lymphangiography and bone scan before 
radiation therapy or hormonal treatment is 
planned. 
'D iv is ion of Urology, Department of Surgery 
t Department of Pathology 
Address reprint requests to Dr. Kabler at Henry 
Ford Hospital, 2799 West Grand Boulevard 
Detroit, Ml 48202. 
Recent studies have indicated that 
elevation of acid phosphatase activity in 
bone marrow aspirate may be the earliest 
indication of advanced carcinoma of the 
prostate (stages C and D). Elevation of bone 
marrow acid phosphatase (BMAP) fre-
quently reveals abnormality before other 
techniques employed in staging prostatic 
carcinoma, such as digital palpation of the 
gland, serum acid phosphatase, skeletal 
metastatic survey, bone scan and lymph-
angiography. BMAP, therefore, is an essen-
tial part of the workup of all patients with 
prostatic carcinoma. Its measurement may 
be critical in determiriing the stage.of the 
disease and appropriate treatment, eg: radi-
cal surgery, radiation therapy or hormonal 
manipulation. 
Mater ia ls and methods 
Thir ty men w i th c l in ica l stage A and 
B adenocarcinoma of the prostate were 
studied. Their ages ranged from 49 to 75 
years. Each patient underwent complete 
evaluation including serum acid and al-
kaline phosphatase, skeletal matastatic sur-
vey, bone scan, lymphangiography and 
BMAP determination. 
The technique of lymphangiography and 
its interpretation in patients with carcinoma 
of the prostate has been reported.^ 
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BMAP was obtained by atraumatic aspira-
tion of 5 cc of bone marrow from the pos-
terior iliac crest This site was chosen in 
preference to the sternum because of the 
known free communication of periprostatic, 
pelvic and paravertebral veins with the mar-
row space of the iliac crest. At the time of 
marrow aspirat ion, a blood sample was 
drawn and the specimens delivered imme-
diately to the laboratory. Because of in-
stability of the enzyme, analyses for acid 
phosphatase were performed within 30 min-
utes of their receipt in the laboratory. Acid 
phosphatase activity was measured by the 
Roy method (thymol phosphaline phos-
phate), as modified for the Dupont ACA.* 
This method has great specificity for prosta-
tic acid phosphatase and minimizes the 
contribution of acid phosphatase of marrow 
cellular, eg: RBC, platelet, origin. Normal 
range for both serum and marrow acid phos-
phatase by this method is 0-0.7 l.U. 
Results 
Fifteen patients (Group I), in whom staging 
studies failed to demonstrate distant meta-
stases, underwent radical retropubic pros-
tatectomy and lymphadenectomy including 
the sacral, obturator, hypograstric, external 
iliac and common iliac nodal drainage to the 
aortic bifurcation. The remaining 15 patients 
(Group II) were found to have stage D dis-
ease. Seven of these patients received irra-
diation therapy to the prostate and its nodal 
drainage, and eight underwent treatment by 
hormonal manipulation. 
In 11 of 15 patients in Group I (73%), 
neoplasm was found to have extended be-
yond the confines of the prostatic capsule. 
Carcinoma was found in the regional lymph-
atics in six patients, the periprostatic tissues 
in fourand seminal vesicles inone. Elevation 
of BMAP (range .90-2.0 I.U.; mean 1.2 l.U.), 
was noted i n l O o f t h e l l patients (91%) only 
three of whom had elevation of serum acid 
phosphatase. One of the 11 patients with 
extraprostatic carcinoma had normal BMAP 
and serum acid phosphatase levels. Of four 
patients with the neoplasm confined to the 
prostate gland, one had deviation of BMAP 
and all had normal serum acid phosphatase. 
Of the 15 patients in Group II with stage D 
carcinoma of the prostate, 13 (87%) had 
elevated BMAP (range .80-7.2 l.U.; mean 
1.9 I.U.). Four of these also had elevated 
serum acid phosphatase. In nine patients, 
this study was normal. Both patients with 
stage D disease and normal BMAP had 
normal serum enzyme levels. 
Other staging studies and their diagnostic 
accuracy in demonstrating advanced (stage 
C and D) disease were lymphangiography 
55%, bone scan 55%, plasma acid phos-
phatase 23% and bone survey 14%. 
Discussion 
The accuracy of BMAP in predicting neo-
plastic dissemination in patients with car-
cinoma of the prostate, and its superiority to 
other staging techniques routinely used in 
this disease, were underscored in this study. 
Thus, of 11 patients found to have local and 
lymphatic extension atthe time of operation, 
10 (91%) had elevated BMAP Three of four 
operated patients in whom the carcinoma 
was confined to the prostate gland had 
normal BMAP (75%) and one patient had 
false positive elevation. Similarly, in 15 pa-
tients with demonstrated stage D metastatic 
disease, BMAP was elevated in 13 (87%). 
As described, other frequently employed 
staging studies were less accurate in predict-
ing extent of the carcinoma, with bone scan 
and lymphangiography demonstrating met-
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astases in 55% of patients, and elevation of 
serum acid phosphatase and abnormal bone 
survey indicating advanced disease in 23% 
and 14%, respectively. These findings do not 
obviate the need for these staging tech-
niques, but suggest they be employed to 
corroborate BMAP, define the exact location 
of metastases when BMAP iselevated and to 
demonstrate, when possible, metastatic car-
cinomaof the prostate in those rare instances 
when BMAP is incorrect. 
The exact mechanism for elevation of 
BMAP is not clear. Probably one or both of 
two mechanisms are responsible for eleva-
tion of this enzyme in the bone marrow, 
while plasma levels remain normal. First, itis 
possible that in those patients with normal 
bone survey and scan, and only locally 
demonstrated periprostatic tumor extension, 
there are in fact microscopic foci of neo-
plasm in the bone marrow, which wi l l later 
become clinically apparent. Second, the 
extensive and free communication of peri-
prostatic, pelvic and paravertebral veins 
with the marrow space of the iliac crest 
suggests that high concentrations of acid 
phosphatase may be delivered to bone mar-
row for sometime priorto equilibration with 
the systemic circulation. Long term follow-
up of this group of patients wil l ultimately 
substantiate or refute this mechanism. 
Summary 
It is concluded that (a) BMAP is the most 
sensitive indicator of stage C and D car-
cinoma of the prostate, (b) BMAP is capable 
of indicating periprostatic or nodal involve-
ment in the apparent absence of osseous 
metastases, (c) lymphangiography and bone 
scan are of especial value in patients with 
false negative BMAP, and in planning radia-
tion therapy or hormonal manipulation in 
patients who are not candidates for radical 
surgery. 
177 
Kabler, Farah, Greenawald, and Cerny 
References 
1. Pontes JE, Alcorn SW, Thomas AJ Jr, and 
Pierce JM Jr: Bone marrow acid phosphatase 
in staging prostatic carc inoma. / U ro l 
114:422, 1975 
2. Veenema RJ: Personal communication. 
3. Cerny JC, Farah R, Rian R and Weckstein ML: 
An evaluation of lymphangiography in stag-
ingcarcinomaofthe prostate./ Urol 113:367, 
1975 
4. ChuaDT, Veenema RJ, Muggia F and Graff A: 
Acid phosphatase levels in bone marrow: 
Value in detecting early bone metastasis from 
carcinoma of the prostate, j Urol 103:462, 
1970 
5. Reynolds RD, Greenberg BR, Martin ND, 
Lucas RN, Gaffney CN and Hawn L: Useful-
ness of bone marrow serum acid phosphatase 
in staging carcinoma of the prostate. Cancer 
32:181, 1973 
6. Yam LT: Clinical significance of the human 
acid phosphatases. A review. Amer J Med 
56:604, 1974 
7. Sy FA, Gursel EO and Veenema RJ: Positive 
random iliac bone biopsy in advanced prosta-
tic cancer. Urology 2:125,1973 
8. Roy AV, Bower ME and Hayden JE: Sodium 
thymolphthalein monophosphate. A new 
acid phosphatase substrate with greater spe-
cificity for the prostatic enzyme in serum. C//n 
Chem 17:1093, 1971 
178 
